Allurion Technologies (ALUR) Projected to Post Quarterly Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.63) per share and revenue of $2.95 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 12:30 PM ET.

Allurion Technologies Stock Performance

ALUR opened at $0.80 on Monday. The company has a fifty day moving average price of $1.13 and a two-hundred day moving average price of $1.54. Allurion Technologies has a 1-year low of $0.23 and a 1-year high of $4.18. The company has a market cap of $9.82 million, a P/E ratio of -0.08 and a beta of -0.42.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Allurion Technologies in a research note on Wednesday, January 21st. Loop Capital set a $3.00 price target on Allurion Technologies in a report on Tuesday, February 24th. Finally, Chardan Capital set a $3.00 price objective on Allurion Technologies and gave the company a “buy” rating in a research note on Tuesday, February 24th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Allurion Technologies has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALUR. XTX Topco Ltd increased its position in shares of Allurion Technologies by 43.2% during the second quarter. XTX Topco Ltd now owns 18,670 shares of the company’s stock worth $45,000 after acquiring an additional 5,633 shares in the last quarter. State Street Corp lifted its position in Allurion Technologies by 76.2% in the 4th quarter. State Street Corp now owns 26,135 shares of the company’s stock valued at $32,000 after acquiring an additional 11,300 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Allurion Technologies during the 4th quarter valued at about $74,000. Heights Capital Management Inc. acquired a new position in Allurion Technologies during the 4th quarter valued at about $74,000. Finally, Armistice Capital LLC bought a new stake in Allurion Technologies during the 4th quarter worth approximately $74,000. 21.39% of the stock is currently owned by institutional investors and hedge funds.

About Allurion Technologies

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey.